Blackstone Inc
ELVN icon

Blackstone Inc’s Enliven Therapeutics ELVN Stock Holding History

Blackstone Inc’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.9M Buy
+215,744
New +$9.16M 0.03% 94
2026
Q1 		– Sell
-954,946
Closed -$14.7M – 441
2025
Q4 		$14.7M Sell
954,946
-365,646
-28% -$7.28M 0.06% 88
2025
Q3 		$27M Hold
1,320,592
– – 0.11% 65
2025
Q2 		$26.5M Buy
1,320,592
+558,285
+73% +$10.6M 0.11% 59
2025
Q1 		$15M Buy
762,307
+388,984
+104% +$8.37M 0.06% 66
2024
Q4 		$8.4M Hold
373,323
– – 0.04% 80
2024
Q3 		$9.53M Buy
373,323
+52,143
+16% +$1.21M 0.04% 78
2024
Q2 		$7.51M Buy
321,180
+295,989
+1,175% +$6.23M 0.03% 84
2024
Q1 		$443K Buy
+25,191
New +$386K ﹤0.01% 154

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Blackstone Inc's ELVN Position: Q2 2026 in Review

Blackstone Inc opened a new position in Enliven Therapeutics (ELVN) in Q2 2026: 215,744 shares worth $10.9M. The stake represents 0.03% of the portfolio and ranks #94 among its holdings. This is a return to the name: Blackstone Inc previously reported a position in ELVN as recently as Q4 2025.

Blackstone Inc first reported a position in ELVN in Q1 2024 and has held it in 9 quarters since. The position peaked at $27M in Q3 2025. 211 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Blackstone Inc held 215,744 shares of Enliven Therapeutics worth $10.9M as of Q2 2026.
  • Enliven Therapeutics was a new Blackstone Inc position in Q2 2026.
  • Enliven Therapeutics made up 0.03% of Blackstone Inc's portfolio in Q2 2026, its #94 holding.
  • Blackstone Inc first reported a position in Enliven Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • Blackstone Inc's Enliven Therapeutics position peaked at $27M in Q3 2025.
  • 211 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Blackstone Inc's 13F filing for Q2 2026, filed 14 Aug 2026.